2017 ASCO-SITC Clinical Immuno-Oncology Symposium
A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.
New research into gut bacteria may shed light on the mystery of responsiveness to immunotherapy. The multi-institutional study, presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, showed that patients with metastatic melanoma who responded to anti—PD-1 agents had increased diversity of intestinal microbiome.
When combined with chemotherapy, a vaccine against the human papillomavirus type 16 (HPV16) elicited strong T-cell responsiveness and improved clinical outcomes in patients with advanced cervical cancer.
According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, adoptive T-cell transfer using “nonengineered” T cells is producing durable responses in heavily pretreated patients with lymphoma or multiple myeloma.
In patients with stage III/IV melanoma, intratumoral injections of plasmid interleukin-12 (IL-12) via electroporation enhanced response to immune checkpoint blockade.
The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains an elusive goal.
As Dr Mita reported at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, plinabulin is a small molecule with tumor-inhibiting and immune-enhancing effects.
Durability of benefit—the possibility for sustained remission in patients with previously incurable disease—is already one of the hallmarks of immunotherapy. According to recent statistical analysis, however, this durability may even exceed expectations.
According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, a single intravenous dose of an oncolytic virus can be highly effective in disseminated cancer as well.
According to preliminary data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, when used in combination with either ipilimumab or pembrolizumab, talimogene laherparepvec (T-VEC) demonstrated promising efficacy with minimal added toxicity.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 11
Results 1 - 10 of 11
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512